Macrophage inflammatory protein-3α promotes pancreatic cancer cell invasion

被引:59
作者
Campbell, AS [1 ]
Albo, D [1 ]
Kimsey, TF [1 ]
White, SL [1 ]
Wang, TN [1 ]
机构
[1] Med Coll Georgia, Sect Surg Oncol, Dept Gen Surg, Augusta, GA 30912 USA
关键词
macrophage inflammatory protein-3 alpha; matrix metalloproteinase; CCR6; pancreatic adenocarcinoma;
D O I
10.1016/j.jss.2004.07.013
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Human CC chemokine Macrophage Inflammatory Protein-3alpha (MIP-3alpha) directs inflammatory cell migration through its binding to the transmembrane receptor CCR6. MIP-3alpha has recently been shown to promote tumor cell migration in pancreatic adenocarcinoma by up-regulation of matrix metalloproteinases (MMPs). We hypothesized that MIP-3alpha promotes pancreatic cancer invasion through the up-regulation of MMP-9, a Type 4 collagenase. Materials, Methods, and Results. Immunohistochemistry and RT-PCR confirmed the presence of MIP-3alpha in PANC-1 cells, a human pancreatic adenocarcinoma cell line. MIP-3alpha stimulated the production of both latent and active forms of MMP-9 in PANC-1 by Western analysis. Tumor cell invasion was then evaluated using a modified Boyden chamber invasion assay. MIP-3alpha promoted a dose-dependent increase in pancreatic cancer cell invasion (P < 0.05) at 100 ng/ml. The activity at the putative MIP-3a receptor, CCR6, was demonstrated by receptor blockade. Anti-CCR6 antibody and anti-MMP-9 antibody inhibited MIP-3alpha-stimulated PANC-1 cell invasion of collagen to 37% and 35% of control, respectively (P < 0.05). Conclusions. MIP-3alpha, through its CCR6 receptor, promotes tumor cell invasion by the up-regulation of MMP-9. Molecular based therapy aimed at the inhibition of MIP-3alpha activity through the CCR6 receptor may serve as a future target to prevent tumor cell invasion in pancreatic adenocarcinoma. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:96 / 101
页数:6
相关论文
共 32 条
[1]   Expression of MIP-3α/CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma [J].
Abiko, Y ;
Nishimura, M ;
Kusano, K ;
Nakashima, K ;
Okumura, K ;
Arakawa, T ;
Takuma, T ;
Mizoguchi, I ;
Kaku, T .
ARCHIVES OF ORAL BIOLOGY, 2003, 48 (02) :171-175
[2]  
[Anonymous], 1987, Cancer, V59, P2006
[3]   The AP-1 site and MMP gene regulation: What is all the fuss about? [J].
Benbow, U ;
Brinckerhoff, CE .
MATRIX BIOLOGY, 1997, 15 (8-9) :519-526
[4]   Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials [J].
Bloomston, M ;
Zervos, EE ;
Rosemurgy, AS .
ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (07) :668-674
[5]  
Bramhall SR, 1997, INT J PANCREATOL, V21, P1
[6]   Expression of collagenase (MMPZ), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease [J].
Bramhall, SR ;
Stamp, GWH ;
Dunn, J ;
Lemoine, NR ;
Neoptolemos, JP .
BRITISH JOURNAL OF CANCER, 1996, 73 (08) :972-978
[7]   Regulation of dendritic cell recruitment by chemokines [J].
Caux, C ;
Vandervliet, B ;
Massacrier, C ;
Ait-Yahia, S ;
Vaure, C ;
Chemin, K ;
Dieu-Nosjean, MC ;
Vicari, A .
TRANSPLANTATION, 2002, 73 (01) :S7-S11
[8]   Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites [J].
Dieu, MC ;
Vanbervliet, B ;
Vicari, A ;
Bridon, JM ;
Oldham, E ;
Aït-Yahia, S ;
Brière, F ;
Zlotnik, A ;
Lebecque, S ;
Caux, C .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (02) :373-386
[9]  
EVANS DB, CANC PRINCIPLES PRAC
[10]   Inflammation and the development of pancreatic cancer [J].
Farrow, B ;
Evers, BM .
SURGICAL ONCOLOGY-OXFORD, 2002, 10 (04) :153-169